NATALIE TELLEZ: Open Payments
NPI 1730433947 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$208,686 in 452 payments from 18 companies in 2025. Trend: 2023 $152,264 · 2024 $146,440 · 2025 $208,686
Speaker / faculty: $164,560Travel & lodging: $34,536Food & beverage: $7,110Consulting: $2,480
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 161 | $94,701 |
| ABBVIE INC. | 166 | $88,879 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 52 | $17,962 |
| Otsuka America Pharmaceutical, Inc. | 29 | $6,128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $169 |
| Neurocrine BioSciences, Inc. | 5 | $135 |
| Alkermes, Inc. | 5 | $122 |
| Lundbeck LLC | 4 | $108 |
| Corium, LLC | 5 | $83 |
| Axsome Therapeutics, Inc. | 3 | $70 |
Products named: FANAPT, VRAYLAR, CAPLYTA, REXULTI, TRINTELLIX, INGREZZA, ARISTADA, Azstarys.
Industry payments across TX — which companies pay providers there.
